BGM BGM Group Limited: Nilai bisnis marang pendapatan

Logo perusahaan publik BGM Group Limited (BGM)

BGM Group Ltd faces significant challenges due to its dependence on regulatory approvals and the risks associated with failed clinical trials for new drugs. The company's current price-to-sales valuation is based on the synergy between AI and biopharmaceuticals, with the metric fixed at 2176.41. A diversified molecule portfolio and patent protection create a sustainable barrier to entry for competitors, ensuring the holding's long-term stability.

Multiplikator EV/Sales BGM Group Ltd (BGM): kanggo periode 23.11.2025 - 20.11.2026

bgm.ltd - rincian analitis lan metrik utama (BGM)

- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi saham perusahaan:
- informasi babagan dhuwit lan arus kas:
Analisis wiwitan perusahaan:BGM Group Ltd
Barang unggulan BGM Group Ltd

To minimize capital losses during long-term asset ownership, it is necessary to compare the total enterprise value with annual turnover, ignoring the debt load. The EV/Sales trend allows for an assessment of the premium paid for BGM Group Ltd (BGM) against the risks of clinical trial failures and regulatory dependence, determining the extent to which the company's market valuation is justified by current operating revenue in the orphan drug sector.